A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Clinical trial NCT02556892 · COMPLETED
Trial details
- NCT number
- NCT02556892
- Sponsor
- Janssen Pharmaceutical K.K.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-03
- Primary completion
- 2018-08-20
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.